newsfilter
← Latest News
PR Newswire·

BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day

BIOA
  • BioArctic AB's partner Eisai published a simulation projecting Leqembi sales of approximately JPY 300 billion (SEK 17.6 billion) for fiscal year 2028, ending March 2029.
  • The presentation was disclosed by BioArctic on May 25, 2026, at 09:15 CET in compliance with the EU Market Abuse Regulation.
  • Leqembi is approved in 53 countries with regulatory reviews ongoing in 6 additional countries.
  • Intravenous maintenance dosing every four weeks is approved in 7 countries, including the US, UK, China, and Japan.
  • Leqembi Iqlik™ is approved in the US for subcutaneous maintenance dosing using an autoinjector.
  • A new drug application for a subcutaneous formulation was submitted in Japan in November 2025.
  • Leqembi was included in China's 'Commercial Insurance Innovative Drug List' in December 2025.
  • The US FDA granted Priority Review to Eisai's supplemental application for a subcutaneous starting dose in January 2026, with a PDUFA date of August 24, 2026.
  • The subcutaneous formulation application was accepted for priority review in China in January 2026.
  • Eisai's Phase 3 AHEAD 3-45 study for preclinical Alzheimer's disease is ongoing with full recruitment completed in October 2024.
  • The Tau NexGen study for Dominantly Inherited Alzheimer's disease has included lecanemab as the backbone therapy since January 2022.
  • BioArctic maintains a long-term collaboration with Eisai since 2005 regarding Alzheimer's disease drug development.
  • BioArctic holds commercialization rights for lecanemab in the Nordic region while Eisai manages global regulatory interactions.
  • BioArctic is entitled to sales milestone payments and royalties on global sales without incurring development costs for lecanemab.
  • BioArctic is a Swedish biopharma company listing on Nasdaq Stockholm that also researches treatments for Parkinson's disease and ALS.